Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$38 Mln
P/E Ratio
--
P/B Ratio
1.8
Industry P/E
--
Debt to Equity
0
ROE
-0.67 %
ROCE
-195.78 %
Div. Yield
0 %
Book Value
1968.61
EPS
-1930.84
CFO
$-46.76 Mln
EBITDA
$-54.77 Mln
Net Profit
$-52.41 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Lantern Pharma (LTRN)
| 7.21 | -10.00 | -5.00 | -43.00 | -20.78 | -- | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Lantern Pharma (LTRN)
| -25.29 | -29.14 | -24.31 | -58.55 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,226.85 | 20.76 | 23.13 | |
| 296.28 | 9,219.66 | 24.15 | 58.42 | |
| 24.72 | 10,361.50 | -- | -28.77 | |
| 101.38 | 9,388.25 | 28.84 | 14.16 |
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial... in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas. Address: 1920 McKinney Avenue, Dallas, TX, United States, 75201 Read more
President, CEO & Director
Mr. Panna Sharma PH.D.
President, CEO & Director
Mr. Panna Sharma
Headquarters
Dallas, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Lantern Pharma Inc (LTRN) stood at $ 25,572 Mln as on 31-Dec-24
The share price of Lantern Pharma Inc (LTRN) is $3.42 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Lantern Pharma Inc (LTRN) has given a return of -20.78% in the last 3 years.
Lantern Pharma Inc (LTRN) has a market capitalisation of $ 38 Mln as on 16-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Lantern Pharma Inc (LTRN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Lantern Pharma Inc (LTRN) and enter the required number of quantities and click on buy to purchase the shares of Lantern Pharma Inc (LTRN).
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas. Address: 1920 McKinney Avenue, Dallas, TX, United States, 75201
The CEO & director of Mr. Panna Sharma PH.D.. is Lantern Pharma Inc (LTRN), and CFO & Sr. VP is Mr. Panna Sharma.
There is no promoter pledging in Lantern Pharma Inc (LTRN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,031
|
|
|
989
|
|
|
950
|
|
|
915
|
| Lantern Pharma Inc. (LTRN) | Ratios |
|---|---|
|
Return on equity(%)
|
-195.78
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Lantern Pharma Inc (LTRN) was $0 Mln.
$-0.07
(
